New Drugs for Asthma, Kidney Disease, HIV Are On the Horizon

A new biologic for severe asthma, a drug for anemia related to chronic kidney disease (CKD) and a long acting pre-exposure prophylaxis (PrEP) for HIV-1 are among the first-in-class therapies featured in OptumRx’s Q1 2022 Drug Pipeline Insights Report. In addition to these new drugs, the PBM also calls attention to the likelihood of more COVID-19 vaccines and treatments receiving full approval and additional uses in 2022.

Tezepelumab (brand name Tezspire) was approved by the FDA for maintenance treatment of severe asthma in December 2021. Many biologics for severe asthma are already on the market, but these drugs target asthma subtypes determined by baseline blood eosinophil counts, according to the OptumRx report. On the other hand, tezepelumab, developed by AstraZeneca and AmGen Inc., has been developed with a broader indication.

© 2022 MMIT

Freelance Reporter Freelance Reporter

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2022/01/WordPress-Featured_AdobeStock_414656276_Editorial_Use_Only.jpg
January 13

In Blow to PBMs, CMS Floats Reform of Part D Price Concessions

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2022/01/WordPress-Featured_AdobeStock_68809113.jpg
January 13

PBMs Will Face Pressure From Transparency Rules, Startups

READ MORE
https://www.mmitnetwork.com/wp-content/uploads/2022/01/WordPress-Featured-Image_Reality-Check_Breast-Cancer.jpg
January 13

Payer Groups Applaud CMS Coverage Decision on Aduhelm

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today